(Bloomberg) The global push to use artificial intelligence to find new medicines faces a crucial test as one front-runner starts approaching late-stage trials for a drug discovered by algorithms. Most Read from BloombergWall Street Divided Over Just How Aggressive Fed Cutting Will BeUBS Strategists See Far Deeper Fed Rate Cuts Than What Markets Are PricingIsrael Latest: Yellen Sees Limited Global Economic Impact So FarChina Weighs Ending Freeze on Boeing With 737 Max Deal in USBiden, Xi to An
Insilico Medicine (“Insilico”), a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety,